Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,292 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,292 shares of Pharvaris stock in a transaction on Friday, August 14th. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84. Following the completion of the sale, the chief executive officer directly owned 130,625 shares of the company’s stock, valued at approximately $4,541,831.25. The trade was a 1.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Berndt Modig also recently made the following trade(s):

• On Monday, June 15th, Berndt Modig sold 2,291 shares of Pharvaris stock. The shares were sold at an average price of $31.07, for a total transaction of $71,181.37.

Pharvaris Price Performance

Shares of NASDAQ PHVS opened at $36.10 on Wednesday. The company has a 50-day moving average price of $33.88 and a 200-day moving average price of $30.23. The stock has a market capitalization of $2.36 billion, a P/E ratio of -11.84 and a beta of -2.31. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $36.93.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, equities research analysts anticipate that Pharvaris N.V. will post -3.15 earnings per share for the current fiscal year.

Trending Headlines about Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Pharvaris. Its projections still anticipate a significant improvement in profitability over time, including positive earnings of $3.09 per share in fiscal 2029. HC Wainwright Predicts Pharvaris’ Q4 Earnings
• Neutral Sentiment: HC Wainwright issued estimates for Pharvaris’ upcoming quarters and future fiscal years, reflecting continued near-term losses as the company advances its development programs. The firm expects losses of $3.41 per share in fiscal 2026 and $3.30 per share in fiscal 2027, followed by a smaller $0.56-per-share loss in fiscal 2028.
• Negative Sentiment: HC Wainwright reduced its fiscal 2026 EPS forecast to a loss of $3.41 from $2.98, and cut its fiscal 2027 forecast to a loss of $3.30 from $2.41. It also lowered estimates for third-quarter 2026, fourth-quarter 2026, fiscal 2028 and fiscal 2029, indicating expectations for greater near-term cash burn and a slower path to profitability.
• Negative Sentiment: Chief Executive Officer Berndt Modig sold 2,292 PHVS shares for approximately $79,693 at an average price of $34.77. He retained 130,625 shares, so the transaction was relatively small, but insider selling can weigh modestly on investor sentiment. SEC insider ownership filing

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. venBio Partners LLC purchased a new stake in shares of Pharvaris in the 2nd quarter valued at about $160,569,809,000. Wellington Management Group LLP purchased a new stake in Pharvaris during the 3rd quarter valued at about $43,282,000. 5AM Venture Management LLC bought a new position in shares of Pharvaris in the second quarter worth approximately $27,581,008,000. Seven Fleet Capital Management LP bought a new stake in Pharvaris in the 2nd quarter worth $26,782,245,000. Finally, Paradigm Biocapital Advisors LP grew its stake in shares of Pharvaris by 72.7% in the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after purchasing an additional 772,583 shares during the last quarter.

Analyst Ratings Changes

Several analysts have recently commented on PHVS shares. Wells Fargo & Company assumed coverage on shares of Pharvaris in a report on Wednesday, July 15th. They issued an “overweight” rating and a $55.00 target price for the company. UBS Group set a $74.00 price objective on shares of Pharvaris in a research note on Wednesday, May 13th. HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research report on Friday, July 17th. Finally, Royal Bank Of Canada raised their price objective on shares of Pharvaris from $51.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.08.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.